Efficacy of a hypnosis-based intervention to improve well-being during cancer: a comparison between prostate and breast cancer patients by Grégoire, Charlotte et al.
RESEARCH ARTICLE Open Access
Efficacy of a hypnosis-based intervention to
improve well-being during cancer: a
comparison between prostate and breast
cancer patients
C. Grégoire1*, H. Nicolas2, I. Bragard1, F. Delevallez3, I. Merckaert3, D. Razavi3, D. Waltregny4, M.-E. Faymonville5
and A. Vanhaudenhuyse5
Abstract
Background: Prostate and breast cancer can have a lot of negative consequences such as fatigue, sleep difficulties
and emotional distress, which decrease quality of life. Group interventions showed benefits to emotional distress
and fatigue, but most of these studies focus on breast cancer patients. However, it is important to test if an effective
intervention for breast cancer patients could also have benefits for prostate cancer patients.
Methods: Our controlled study aimed to compare the efficacy of a self-hypnosis/self-care group intervention to
improve emotional distress, sleep difficulties, fatigue and quality of life of breast and prostate cancer patients. 25 men
with prostate cancer and 68 women with breast cancer participated and were evaluated before (T0) and after (T1) the
intervention.
Results: After the intervention, the breast cancer group showed positive effects for anxiety, depression, fatigue, sleep
difficulties, and global health status, whereas there was no effect in the prostate cancer group. We showed
that women suffered from higher difficulties prior to the intervention and that their oncological treatments
were different in comparison to men.
Conclusion: The differences in the efficacy of the intervention could be explained by the baseline differences.
As men in our sample reported few distress, fatigue or sleep problems, it is likely that they did not improve on these
dimensions.
Trial registration: ClinicalTrials.gov (NCT02569294 and NCT03423927). Retrospectively registered in October 2015 and
February 2018 respectively.
Keywords: Breast cancer, Prostate cancer, Group intervention, Hypnosis, Self-care
Background
Prostate cancer is a major pathology in industrialized
countries [1, 2] and the second leading cause of death in
males [3, 4] whereas breast cancer is the most frequently
diagnosed cancer and the leading cause of cancer death
in females [1]. Survival rates have increased worldwide
[5–7] and more and more patients are living with the
consequences of cancer. These two cancers are very
common, are gender specific (100% of prostate cancer
patients being male, about 99% of breast cancer patients
being female), and both impact the sexual organs.
Prostate cancer is frequently diagnosed in later stages
because it progresses slowly, leading to delayed treatment
[8]. Common treatments for prostate cancer include
radical prostatectomy, radiation therapy or brachytherapy,
hormonotherapy, or watchful waiting [7, 9, 10].
Treatments for breast cancer include surgery, radiation
therapy, chemotherapy, and hormonotherapy [11]. These
* Correspondence: ch.gregoire@uliege.be
1Public Health Department and Sensation and Perception Research Group,
GIGA Consciousness, University of Liège, Liège, Belgium
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Grégoire et al. BMC Cancer  (2018) 18:677 
https://doi.org/10.1186/s12885-018-4607-z
treatments can have a lot of common negative side
effects on patients: pain, physical dysfunction, fatigue,
sleep disturbances [12–18], as well as cognitive difficul-
ties [19–24]. These symptoms can contribute to the
development of emotional distress, mostly anxiety and
depression [13, 25–29], and can postpone or impede
patients’ return to work [30–32].
In addition, prostate cancer has several specific conse-
quences, such as erectile dysfunction, loss of libido,
decreased orgasmic sensation [17, 33–37], or urinary and
bowel problems such as incontinence [17, 35, 38, 39].
Breast cancer also has negative impacts on women’s
femininity as it alters or removes symbols of femininity
such as breasts, menstruation, or fertility [40, 41]. These
difficulties encountered by both prostate and breast cancer
patients impact a couple’s intimacy, communication and
sexuality [12, 42–46], and can persist for years after the
end of treatment [47–51].
In oncology settings, several psychological interventions
have been tested in order to improve some of these symp-
toms. Group interventions such as cognitive-behavioural
therapy (CBT) and hypnosis have shown benefits for
emotional distress and fatigue [52–59]. However, most of
these studies focus on breast cancer patients, and prostate
cancer patients are often neglected in psycho-oncological
studies [7, 60]. Several systematic reviews investigated
non-pharmacological interventions to improve prostate
cancer patients’ well-being. In their review, Keogh et al.
[61] showed that physical activity is helpful to improve
general quality of life and to decrease fatigue in such
patients. Other systematic reviews have also shown the
benefits of physical exercise to improve quality of life [62]
and fatigue [63, 64] in these patients. Larkin et al. [64] also
showed the efficacy of CBT-based interventions to
manage cancer-related fatigue. In their systematic review,
Chambers et al. [65] showed the efficacy of CBT-based
interventions to improve quality of life, psychological
adjustment, and to decrease worry at a 6-month follow-up
in prostate cancer patients. They also showed the positive
effects of stress-management interventions on quality of
life after prostate surgery. Despite these encouraging
results, there is a need for more data in order to confirm
the efficacy of such interventions.
Given the important negative consequences of prostate
and breast cancers, it is important to design interven-
tions to help patients to cope with the effects of treat-
ments [34, 52, 66].
Objectives
The aim of our longitudinal study was to test if an effect-
ive intervention for breast cancer patients could also have
benefits for prostate cancer patients in terms of decreased
anxiety, depression, sleep difficulties and fatigue, and




At the end of their treatment, each eligible prostate
cancer patient from two oncology services (CHU Liège
and CHR Citadelle, Belgium) was directly met or
contacted by phone by the experimenter to be informed
of the study’s aims and design. 152 eligible patients
were informed about the study, of which 101 refused to
participate. Reasons for refusal were “I am not inter-
ested in the proposed intervention”, “I have no time for
this”, “I can manage myself”, and “it is too far from
home”. Five of the 51 remaining patients dropped out
of the study because they no longer had the time or
suffered from health complications, leaving a final sam-
ple of 46 participants. Of these, 25 agreed to participate
in the group intervention, and were divided into 5
groups of 4 to 7 patients, whereas 21 did not agree to
participate in the intervention because they were not
interested or had no time for the intervention. How-
ever, they agreed to complete the questionnaires. These
patients were included in the control group. Inclusion
criteria were ≥ 18-years-old, ability to read, write and
speak French, prostate cancer diagnosis, treatment with
surgery and/or radiotherapy. Exclusion criteria were me-
tastases or cancer recurrence at the moment of inclusion,
and major cognitive or psychiatric disorder.
Breast cancer
Breast cancer patients (only from CHU Liège) were
directly met or contacted by phone by the experimenter
and asked to participate in a group intervention during
or after their treatment. We used previously published
data of patients included in self-hypnosis/self-care group
interventions [52, 67]. In these studies, patients could
choose between yoga, cognitive-behavioural therapy, or
self-hypnosis/self-care groups. In this study, we focused
on patients included in the self-hypnosis/self-care group.
Of 426 eligible patients contacted, 114 patients were
included in the study. Most common reasons for refusal
were “I am not interested in the proposed intervention”,
“I have no time for this”, “I can manage myself” and “it
is too far from home”. Fifteen patients dropped out of
the study, mostly because they no longer had the time,
they did not like the intervention, or they developed
health complications. Sixty-eight of the 99 remaining
patients chose to participate in the hypnosis group and
were divided into 13 groups of 3 to 8 participants.
Twenty-four patients who did not agree to participate in
any group were recruited to form the control group.
Inclusion criteria were ≥ 18-years-old, ability to read,
write and speak French, breast cancer diagnosis. Exclu-
sion criteria were metastases or cancer recurrence at the
Grégoire et al. BMC Cancer  (2018) 18:677 Page 2 of 11
moment of inclusion, benefiting from palliative care, and
major cognitive or psychiatric disorder.
All participants had to complete an informed consent
before starting the study.
The differences in the sample sizes are due to some
recruitment difficulties encountered only for the prostate
cancer patients. No a priori sample size calculation was
performed before the study.
Intervention
Self-hypnosis/self-care intervention included six
120-min sessions. For the prostate cancer patients,
sessions were scheduled on a monthly basis, whereas for
the breast cancer patients, they took place every 2
weeks. It means that for prostate cancer patients, the
intervention lasted 6 months (1 session per month), and
that for breast cancer patients it lasted 3 months (2 ses-
sions per month). The sessions combined self-hypnosis
exercises and self-care techniques and were developed
by one of the authors (M-E.F) [68, 69]. This approach
fosters engagement in activities, adaptation to the
disease, its treatments and side effects, and well-being
through discussions and tasks. Tasks are based on
self-care techniques and address several topics such as
adjusting self-expectation, improving self-esteem, assert-
iveness, finding one’s own personal needs and boundar-
ies, etc. At the end of each session, a 15-min hypnosis
exercise was conducted by the therapist and each
participant received CDs with the different exercises to
encourage at-home training [52, 67, 68]. This interven-
tion aims to help patients to be an actor of their
well-being, and we give them practical tasks to reactivate
this active role in their improvement after cancer. Dur-
ing the duration of the study, each participant benefited
from their usual oncological and medical care, and indi-
vidual psychological care if needed. Patients from the
control groups did not participate in the intervention
and only benefited from usual care.
Measures
Data were collected through questionnaires:
– Medical and sociodemographic data such as age,
gender, language, family composition, professional
occupation, personal history of cancer and
treatment received were collected.
– Hospital Anxiety and Depression Scale (HADS) [70]
measures anxiety (7 items) and depression (7 items)
during the past week.
– European Organization for Research and Treatment
of Cancer - Quality of Life Core Questionnaire-30
(EORTC-QLCQ30) [71] was developed to assess
quality of life and incorporates 5 functional scales
(physical, role, emotional, cognitive and social
functioning) and 9 symptom-related items (fatigue,
nausea and vomiting, pain, dyspnea, insomnia,
appetite loss, constipation, diarrhea, and financial
difficulties). A global health status can also be
calculated. In this paper, only the fatigue scale and
the global health status are used, as we focus on
these variables.
– Insomnia Severity Index (ISI) [72] is a 7-item scale
measuring the participant’s sleep complaints and
the associated distress.
All questionnaires were administrated twice: before
(T0) and after (T1) the intervention.
Data analysis
All statistical analyses were performed using Statistica
13.3 (TIBCO Software Inc.). Baseline (T0) demographic,
medical, and psychological data were compared between
the treatment and control groups of each population to
test initial group equivalency with MANOVA and
Chi-square tests. To be considered for data analysis,
patients had to complete the two assessments (T0 and
T1). Group-by-time changes in depression, anxiety,
global health status, fatigue and sleep difficulties were
processed using multivariate analysis of variance with
repeated measures (MANOVA), followed by post-hoc
comparisons (Tukey’s HSD test). Effect sizes for standar-
dised differences in means between times of evaluation
were calculated using Cohen’s d, with interpretation as
follows: “small” (< 0.20–0.50), “medium” (0.50–0.80),
and “large” effect size (> 0.80) [73]. All tests were
two-tailed and the results were considered to be signifi-
cant at p < 0.05. Alpha was set at 0.05.
Results
The average attendance rate was 5.3 sessions for prostate
cancer patients and 5.4 for breast cancer patients. The
demographic and medical data of the sample are displayed
in Table 1.
Impact of the intervention on emotional distress, sleep
difficulties, fatigue and quality of life in women with
breast cancer
Both the control and the treatment groups were similar
at baseline, except for the stage of the disease and the
education level (See Table 1). A multivariate analysis of
variance of the variables with repeated measures for
time of evaluation showed a significant effect of time
(F(5) = 2.59; p = 0.031) and a significant group-by-time
interaction effect (F(5) = 2.76; p = 0.023). Post-hoc
comparisons revealed a decrease in anxiety (p = .000),
depression (p = .001), fatigue (p = .003) and sleep diffi-
culties (p = .018) and an increase in global health status
(p = .020) among women with breast cancer who
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Table 1 Demographic and medical data of the sample












Mean (SD) 54.3 (10) 52.5 (6.8) .535 64.11 (5.8) 65.7 (4.4) .330
Range 29–72 39–65 47–73 58–75
Cultural origin, N (%)
Occidental Europe 66 (97.0) 0 NAa 25 (100) 21 (100) NAa
Near and Middle East 1 (1.5) 0 0 0
African 1 (1.5) 0 0 0
Missing data 0 24 (100) 0 0
Marital status, N (%)
Single 5 (7.4) 1 (4.1) .778 1 (4.0) 0 .544
Married/living with partner 52 (76.5) 18 (75) 20 (80.0) 16 (76.2)
Divorced/separated/widowed 11 (16.2) 5 (20.8) 4 (16.0) 5 (23.8)
Missing data 0 0 0 0
Education level, N (%)
Elementary school or less 0 3 (12.5) .001 1 (4.00) 2 (9.5) .557
Lower secondary school 8 (11.8) 7 (29.2) 1 (4.00) 4 (19.0)
Upper secondary school 21 (30.9) 8 (33.3) 7 (28.00) 5 (23.8)
Bachelor’s degree 6 (8.8) 4 (16.7) 3 (12.00) 1 (4.8)
Master’s degree 29 (42.6) 2 (8.3) 12 (48.00) 8 (38.1)
Post-graduate 4 (5.9) 0 1 (4.00) 1 (4.8)
Missing data 0 0 0 0
Employment status, N (%)
Employed part or full time 9 (13.2) 8 (33.3) .080 8 (32.00) 4 (19.0) .344
Employed, taken time off 38 (55.9) 12 (50) 2 (8.00) 3 (14.3)
Not employed 20 (29.4) 4 (16.7) 15 (60.00) 14 (66.7)
Missing data 1 (1.5) 0 0 0
Patient medical history
Time since diagnosis (months)
Mean (SD) 7.1 (5.1) 5.8 (5.0) .368 6.16 (3.52) 6.00 (4.3) .894
Range 1–27 0.5–19 1–15 2–22
Cancer stage, N (%)
0 1 (1.5) 3 (12.5) 0 0
1 37 (54.4) 13 (54.2) 0 0
2 22 (32.4) 3 (12.5) .022 0 0
3 5 (7.4) 0 0 0
Missing data 3 (4.4) 5 (20.8) 25b 21b
Surgery, N (%)
Yes 68 (100) 23 (95.8) NAa 25 (100) 21 (100) NAa
No 0 0 0 0
Missing data 0 1 (4.2) 0 0
Chemotherapy (CT), N (%)
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participated in the intervention (see Table 2). The
analyses of the effect sizes revealed one medium effect
size for the evolution of anxiety before and after the
intervention, in the treatment group. All other effect
sizes in this group were small.
Impact of the intervention on emotional distress, sleep
difficulties, fatigue and quality of life in men with
prostate cancer
Both the control and the treatment groups were similar at
baseline (See Table 1). Multivariate analysis of variance of
Table 1 Demographic and medical data of the sample (Continued)










CT completed 27 (39.7) 7 (29.2) .727 0 0 NAa
During CT 20 (29.4) 8 (33.3) 0 0
No CT 21 (30.9) 8 (33.3) 25 (100) 21 (100)
Missing data 0 1 (4.2) 0 0
Radiation therapy (RT), N (%)
RT completed 30 (44.1) 6 (25) .280 1 (4.0) 0 .354
During RT 6 (8.8) 2 (8.3) 0 0
Not yet started 16 (23.5) 10 (41.7) 0 0
No RT 16 (23.5) 5 (20.8) 24 (96.0) 21 (100)
Missing data 0 1 (4.2) 0 0
Hormonal therapy (HT), N (%)
During HT 38 (55.9) 8 (33.3) .209 2 (8.0) 1 (4.8) .658
Not yet started 23 (33.8) 11 (45.8) 0 0
No HT 7 (10.3) 4 (16.7) 23 (92.0) 20 (95.2)
Missing data 0 1 (4.2) 0 0
Bold values indicate significant difference (p < .05)
aNA (Not applicable) when missing data impeded the analysis, or when the two groups are exactly equivalent (p = 1)
bAll prostate cancer patients were recruited after their surgery and none had metastases
Table 2 Evolution of the data after the intervention in each population
Breast cancer group
Treatment group (N = 68) Control group (N = 24)
T0 T1 Evolution (T0-T1) Effect size T0 T1 Evolution (T0-T1) Effect size
Mean (SD) Mean (SD) p Cohen’s d Mean (SD) Mean (SD) p Cohen’s d
HADS – Anxiety 8.76 (4.14) 6.70 (3.58) .000 0.66 7.17 (2.96) 7.58 (3.40) .916 −0.13
HADS - Depression 5.02 (3.16) 3.84 (3.01) .001 0.47 4.13 (3.72) 4.04 (3.00) .999 0.04
EORTC – Global Health Status 59.19 (16.23) 65.40 (15.83) .020 −0.38 56.94 (20.21) 58.33 (19.19) .980 −0.07
EORTC – Fatigue 52.94 (26.05) 44.77 (21.72) .003 0.41 51.85 (30.68) 46.30 (25.94) .537 0.27
Insomnia Severity Index 12.65 (6.50) 10.60 (6.15) .018 0.40 10.54 (6.73) 12.00 (5.54) .618 −0.20
Prostate cancer group
Treatment group (N = 25) Control group (N = 21)
T0 T1 Evolution (T0-T1) Effect size T0 T1 Evolution (T0-T1) Effect size
Mean (SD) Mean (SD) p Cohen’s d Mean (SD) Mean (SD) p Cohen’s d
HADS – Anxiety 6.50 (3.06) 4.88 (2.98) .085 0.50 4.76 (3.59) 5.71 (3.81) .545 −0.30
HADS - Depression 3.46 (2.47) 3.44 (2.89) .992 0.01 4.19 (3.28) 5.05 (4.85) .516 −0.29
EORTC – Global Health Status 67.67 (14.30) 69.33 (15.54) .969 −0.15 64.29 (20.94) 65.48 (25.45) .983 −0.07
EORTC – Fatigue 32.44 (12.39) 34.22 (16.01) .876 −0.11 32.27 (27.87) 29.63 (29.47) .908 0.14
Insomnia Severity Index 8.04 (5.98) 6.92 (5.87) .704 0.23 6.95 (5.13) 5.86 (4.29) .688 0.28
Bold values indicate significant effects
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the variables with repeated measures for time of
evaluation revealed no significant effect of time or group
and no significant interaction effect in men with prostate
cancer. Post-hoc comparisons showed no significant
evolution of the data in each group after the intervention
(see Table 2).
Analysis of the baseline differences between women with
breast cancer and men with prostate cancer
To understand these observed differences between men
with prostate cancer and women with breast cancer, we
conducted a multivariate analysis of variance on the
baseline data from the two treatment groups. A significant
effect of sex was shown (F(5) = 3.70; p = .004). Post-hoc
comparisons revealed significant baseline difference
between men with prostate cancer and women with breast
cancer: women suffered from higher anxiety (p = .048),
fatigue (p = .003) and sleep difficulties (p = .013) before the
intervention, in comparison to men with prostate cancer.
In addition, women were younger than men (p = .000) and
the treatment they received differed. All men were off
treatment when they were included in self-hypnosis/self--
care group (surgery (N = 25), radiotherapy (N = 1), hormo-
notherapy (N = 2)), while the majority of women were still
on treatment at the time of the study (chemotherapy (N =
20), radiation therapy (N = 6) or hormonal therapy (N =
38)). The detailed baseline comparisons of the two treat-
ment groups are displayed in Table 3.
Discussion
In this study, we compared the efficacy of a self-hypnosis/
self-care group intervention to improve well-being between
men with prostate cancer and women with breast cancer.
Our results revealed an improvement in anxiety, depres-
sion, fatigue, sleep difficulties and global health status in
women with breast cancer whereas no significant improve-
ment was shown among men with prostate cancer.
As these results were unexpected, we decided to
compare the two treatment groups at baseline. It appeared
that the two populations differed at baseline on several
variables: women experienced more anxiety, more fatigue,
and more severe sleep difficulties. They were also younger
than men. These baseline psychological differences could
be explained by the fact that most women in our sample
endured several treatments (surgery, chemotherapy,
radiation therapy and/or hormonal therapy), whereas men
mostly received only one surgical intervention. These
multimodal treatments could negatively impact the
women’s well-being, as they are known to cause a lot of
negative secondary effects, as described above. These
differences in emotional distress observed between men
and women were also reported in previous studies on
depressive patients [74], cancer patients [68, 75–77],
gastroenterology patients [78, 79] and the general popula-
tion [80].
These baseline differences between breast and prostate
cancer patients could be a major explanation for our un-
expected results observed after the self-hypnosis/self-care
intervention. Indeed, as men in our sample did not suffer
from high distress, fatigue, sleep problems or low quality
of life at baseline, it is likely that their improvement on
these variables is low and not significant. On the contrary,
women showed high levels of anxiety, fatigue and sleep
difficulties, and a lower global health status at baseline.
Our results can also be linked to the difference in the
moment at which the intervention took place for men and
women. Most men in our sample had already completed
their treatment, where the majority of them only received
surgery, but a lot of women were still being treated for
cancer at the time of the intervention. It is possible that an
intervention aimed at improving psychological well-being is
more efficient if provided during treatment rather than
afterwards, mostly because the treatments are generally
highly distressing.
Our results could be explained by the men’s tendency to
express higher a need for information than for psycho-
logical help, and to rarely use available psychological
interventions [7, 81, 82]. According to our clinical practice,
men with prostate cancer are generally convinced that their
surgery will cure them and they discover its negative side
effects after several weeks or months. A belief that partici-
pating in a psychological intervention will make them less
masculine, weaker or more vulnerable is also common.
These beliefs could explain the lack of interest in psycho-
logical interventions shown by other studies [7, 45, 83, 84].
Women with breast cancer, on the contrary, report higher
psychological and support needs [7, 45, 81, 82, 85]. As our
intervention did not focus on cancer and medical
information, but proposed psychological support, sharing
of experiences, and learning of self-care techniques and
self-hypnosis exercises, it is possible that it did not address
men’s needs but was more efficient in addressing women’s
needs. In addition, several studies have highlighted the
importance of proposing individualized approaches to help
men at a psychological level, as some of them are reluctant
to talk about their difficulties in group settings [86, 87].
Finally, our contrasting results could also be linked to
the format of the intervention. Women participated in 6
sessions occurring twice a month, while men attended 6
monthly sessions. It is possible that the frequency of the
sessions impacts the efficacy of the intervention. Men
met less frequently and had to deal with their difficulties
on their own for longer periods of time without the
support of the group, which could impact the way they
implemented the techniques and improved over time.
However, we previously showed that monthly
self-hypnosis/self-care learning sessions were efficient to
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Table 3 Baseline differences between breast and prostate cancer patients (Treatment groups only)
Breast cancer (N = 68) Prostate cancer (N = 25) Baseline comparison (p)
Patients’ demographics
Age (years)
Mean (SD) 54.3 (10) 64.11 (5.8) .000
Range 29–72 47–73
Cultural origin, N (%)
Occidental Europe 66 (97.0) 25 (100) .687
Near and Middle East 1 (1.5) 0
African 1 (1.5) 0
Missing data 0 0
Marital status, N (%)
Single 5 (7.4) 1 (4.00) .879
Married/living with partner 52 (76.5) 18 (72.00)
Divorced/separated/widowed 11 (16.2) 4 (8.00)
Missing data 0 2 (8.00)
Education level, N (%)
Elementary school or less 0 1 (4.00) .443
Lower secondary school 8 (11.76) 1 (4.00)
Upper secondary school 21 (30.88) 7 (28.00)
Bachelor’s degree 6 (8.82) 1 (4.00)
Master’s degree 29 (42.65) 12 (48.00)
Post-graduate 4 (5.88) 1 (4.00)
Missing data 0 2 (8.00)
Employment status, N (%)
Employed part or full time 9 (13.2) 8 (32.00) .000
Employed, taken time off 38 (55.9) 2 (8.00)
Not employed 20 (29.4) 15 (60.00)
Missing data 1 (1.5)
Patients’ medical history
Time since diagnosis (months)
Mean (SD) 7.1 (5.1) 6.16 (3.52) .381
Range 1–27 1–15
Surgery, N (%)
Yes 68 (100) 25 (100) 1.00
No 0 0
Missing data 0 0
Chemotherapy (CT), N (%)
CT completed 27 (39.7) 0 .000
During CT 20 (29.4) 0
No CT 21 (30.9) 25 (100)
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improve the global quality of life in chronic pain patients
[68, 69].
There are several limitations to our study. First, our
sample is quite small, especially for the men with prostate
cancer. In addition, no a priori sample size calculation was
performed before starting the study. Future studies are
needed, with exactly the same design of treatment, to
allow a generalisation of our results. The difference in the
number of patients included for each cancer could be ex-
plained by the results of Clover et al. [88]. They recruited
311 patients with different tumour localisations (including
breast and prostate) and showed that the patients cur-
rently on treatment were more likely to ask for psycho-
logical help than patients not currently on treatment. In
addition, women with cancer, especially younger ones, ex-
perienced a higher need for psychological help. It is then
understandable that our sample includes a lot of younger,
in treatment women. Second, women in the treatment
group had more severe cancers than women in the control
group. This could have impact our results. Finally, as ex-
plained above, the intervention was not provided to men
and women with the same frequency, which can impact
its efficacy, our results and their generalisation.
However, this is one of the first studies comparing the
efficacy of a psychological intervention between men with
prostate cancer and women with breast cancer, which is of
great interest as prostate patients are rarely the focus of
psycho-oncological studies [7, 60]. Therefore, our results
highlight the importance of considering the gender of the
participants before designing and providing an interven-
tion in oncology settings. Our results also open different
research perspectives. First, as already highlighted in the
scientific literature [89], it seems essential to design differ-
ent psychological interventions for cancer patients accord-
ing to their gender. As our results suggest, an intervention
efficient for breast cancer patients could not be pertinent
for prostate cancer patients. Several studies suggested that
interventions including some physical activity such as
fitness training, or concrete stress management tech-
niques, were more accepted by men with cancer and more
efficient to improve their well-being [7, 45, 65, 90]. It
seems important to assess the influence of the treatment
trajectory on the efficacy of this intervention, as the type
of treatment and the moment at which the patients par-
ticipate in the intervention appear to impact our results.
Then, future researches should also take into account the
treatment journey of their participants before designing
an intervention. Indeed, prostate cancer patients in the
current study only had surgery, but not other therapy,
such as chemotherapy, radiation therapy, and hormonal
therapy. Therefore, these patients have probably less nega-
tive consequences such as fatigue, sleep difficulties and
emotional distress, which may relate to the low efficacy of
the intervention for these patients. Different strategies
Table 3 Baseline differences between breast and prostate cancer patients (Treatment groups only) (Continued)
Breast cancer (N = 68) Prostate cancer (N = 25) Baseline comparison (p)
Missing data 0 0
Radiation therapy (RT), N (%)
RT completed 30 (44.1) 1 (4.00) .000
During RT 6 (8.8) 0
Not yet started 16 (23.5) 0
No RT 16 (23.5) 24 (96.00)
Missing data 0 0
Hormonal therapy (HT), N (%)
During HT 38 (55.9) 2 (8.00) .000
Not yet started 23 (33.8) 0
No HT 7 (10.3) 23 (92.00)
Missing data 0 0
Patients’ psychological state, Mean (SD)
HADS – Anxiety 8.76 (4.14) 6.50 (3.06) .048
HADS – Depression 5.02 (3.16) 3.46 (2.47) .075
EORTC – Global Health Status 59.19 (16.23) 67.67 (14.30) .066
EORTC – Fatigue 52.94 (26.05) 32.44 (12.39) .003
Insomnia Severity Index 12.65 (6.50) 8.04 (5.98) .013
Bold values indicate significant differences between the two groups
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could be used to adapt this intervention to men with
prostate cancer, such as the inclusion of concrete stress
management techniques. It could also be useful to
propose this intervention longer after men’s treatments,
when they are more likely to experience persistent adverse
effects of treatments. An individual psychological help
could also be suggested before and after the surgery, as
well as a few months later, as the group setting could not
be the best option for men [86, 87], and the group inter-
vention could be proposed to those who experience more
emotional distress. Finally, a more robust design, with an
a priori sample size calculation, identical intervention for
both groups, and similar treatments in both group could
also be used to test the effect of such an intervention on
prostate and breast cancer patients.
Conclusion
In conclusion, our study showed that the intervention
combining self-care and self-hypnosis is efficient to
improve emotional distress, fatigue, and sleep difficulties
in women with breast cancer, but not in men with
prostate cancer. These results could be explained by the
baseline differences between those two populations, in
terms of experienced symptoms, age, and treatments
received. Furthermore, the format of the intervention is
not exactly the same for the two populations. Finally,
men are known to rarely use available psychological in-
terventions, and to express a need for information rather
than for psychological help. This could explain why our
intervention did not improve their well-being. Further
researches are needed in order to assess the efficacy of a
hypnosis-based intervention on different populations in
oncology settings. Our results highlighted the import-
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